MX2017014082A - Nuevas proteinas especificas para cd137. - Google Patents
Nuevas proteinas especificas para cd137.Info
- Publication number
- MX2017014082A MX2017014082A MX2017014082A MX2017014082A MX2017014082A MX 2017014082 A MX2017014082 A MX 2017014082A MX 2017014082 A MX2017014082 A MX 2017014082A MX 2017014082 A MX2017014082 A MX 2017014082A MX 2017014082 A MX2017014082 A MX 2017014082A
- Authority
- MX
- Mexico
- Prior art keywords
- lipocalin muteins
- present description
- bind
- compositions
- nucleic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente descripción provee muteínas de lipocalina humana que se unen a CD137 y pueden ser utilizadas en aplicaciones farmacéuticas, por ejemplo, como agentes anti-cáncer y/o moduladores inmunológicos para el tratamiento o la prevención de enfermedades humanas tales como cáncer, enfermedades infecciosas y enfermedades autoinmunes. La presente descripción también se refiere a métodos para preparar muteínas de lipocalina que se unen a CD137 descriptas en la presente, así como también a composiciones que comprenden dichas muteínas de lipocalina. La presente descripción además se refiere a moléculas de ácido nucleico que codifican dichas muteínas de lipocalina y a métodos para la generación de dichas muteínas de lipocalina y moléculas de ácido nucleico. Además, la solicitud divulga usos terapéuticos y/o de diagnóstico de estas muteínas de lipocalina, así como también composiciones que comprenden una no más de dichas muteínas de lipocalina.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15166184 | 2015-05-04 | ||
| PCT/EP2016/059959 WO2016177762A1 (en) | 2015-05-04 | 2016-05-04 | Proteins specific for cd137 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017014082A true MX2017014082A (es) | 2018-06-28 |
Family
ID=53054879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017014082A MX2017014082A (es) | 2015-05-04 | 2016-05-04 | Nuevas proteinas especificas para cd137. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11261221B2 (es) |
| EP (2) | EP3292137B1 (es) |
| JP (3) | JP6884708B2 (es) |
| KR (1) | KR102734408B1 (es) |
| CN (2) | CN107820500B (es) |
| AU (1) | AU2016258952C1 (es) |
| CA (1) | CA2980839C (es) |
| CL (1) | CL2017002767A1 (es) |
| DK (1) | DK3292137T3 (es) |
| ES (1) | ES2932425T3 (es) |
| IL (1) | IL254516B (es) |
| MX (1) | MX2017014082A (es) |
| NZ (1) | NZ736560A (es) |
| PH (1) | PH12017501583B1 (es) |
| RU (1) | RU2736312C2 (es) |
| SG (1) | SG11201708339QA (es) |
| WO (1) | WO2016177762A1 (es) |
| ZA (1) | ZA201705960B (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2510357B1 (en) | 2009-12-07 | 2016-03-30 | Pieris AG | Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target |
| WO2014076321A1 (en) | 2012-11-19 | 2014-05-22 | Pieris Ag | Novel specific-binding polypeptides and uses thereof |
| CN106573964B (zh) | 2014-05-22 | 2021-07-16 | 皮里斯制药有限公司 | 新型特异性结合多肽及其用途 |
| KR20170105609A (ko) | 2015-01-28 | 2017-09-19 | 피어이스 파마슈티컬즈 게엠베하 | 신생혈관형성에 특이적인 신규한 단백질 |
| JP6783797B2 (ja) | 2015-05-04 | 2020-11-11 | ピエリス ファーマシューティカルズ ゲーエムベーハー | 抗がん融合ポリペプチド |
| EP3292137B1 (en) | 2015-05-04 | 2022-09-07 | Pieris Pharmaceuticals GmbH | Proteins specific for cd137 |
| CA2982034A1 (en) | 2015-05-18 | 2016-11-24 | Pieris Pharmaceuticals Gmbh | Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3) |
| SMT202300026T1 (it) | 2015-05-18 | 2023-03-17 | Pieris Pharmaceuticals Gmbh | Polipeptide di fusione anti-cancro |
| CN108699162A (zh) | 2015-11-30 | 2018-10-23 | 皮里斯澳大利亚有限公司 | 新型抗血管生成融合多肽 |
| TW201725212A (zh) | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | 特異性於降鈣素基因相關胜肽的新穎蛋白 |
| WO2018087108A1 (en) * | 2016-11-09 | 2018-05-17 | Pieris Pharmaceuticals Gmbh | Proteins specific for cd137 |
| CN112004535A (zh) | 2018-03-26 | 2020-11-27 | 4Sc股份公司 | 用于癌症疗法的包括hdac抑制剂和cd137激动剂的组合 |
| TW202035451A (zh) | 2018-07-24 | 2020-10-01 | 美商英伊布里克斯公司 | 含有受限cd3結合域及受體結合區之多重特異性多肽構築體及其使用方法 |
| MX2021000401A (es) * | 2018-07-31 | 2021-03-25 | Pieris Pharmaceuticals Gmbh | Nuevas proteinas de fusion especificas para cd137 y pd-l1. |
| WO2020077257A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | Pd-1 single domain antibodies and therapeutic compositions thereof |
| CA3115089A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | Dll3 single domain antibodies and therapeutic compositions thereof |
| MX2021010039A (es) * | 2019-02-26 | 2021-09-21 | Pieris Pharmaceuticals Gmbh | Novedosas proteinas de fusion especificas para cd137 y gpc3. |
| CN113939307A (zh) * | 2019-03-29 | 2022-01-14 | 皮里斯制药有限公司 | 脂质运载蛋白突变蛋白的吸入施用 |
| CN113677403B (zh) | 2019-04-12 | 2024-12-27 | 豪夫迈·罗氏有限公司 | 包含脂质运载蛋白突变蛋白的双特异性抗原结合分子 |
| CN116348478A (zh) | 2019-11-04 | 2023-06-27 | 皮里斯制药有限公司 | 用于癌症治疗的her2/4-1bb双特异性融合蛋白 |
| KR20230020443A (ko) | 2020-06-05 | 2023-02-10 | 피어이스 파마슈티컬즈 게엠베하 | 4-1bb 표적화 다량체 면역조절제 |
| US20230366884A1 (en) | 2020-09-18 | 2023-11-16 | Pieris Pharmaceuticals Gmbh | Biomarker methods and uses |
| JP2024511620A (ja) | 2021-03-23 | 2024-03-14 | ピエリス ファーマシューティカルズ ゲーエムベーハー | がんの治療のためのｈｅｒ２／４－１ｂｂ二重特異性融合タンパク質 |
| WO2022200478A1 (en) | 2021-03-24 | 2022-09-29 | Pieris Pharmaceuticals Gmbh | Tumor treatment with a 4-1bb/her2-bispecific agent and a her2-targeted tyrosine kinase inhibitor |
| WO2023118497A1 (en) | 2021-12-22 | 2023-06-29 | Pieris Pharmaceuticals Gmbh | Novel il-18 variants |
| WO2023180523A1 (en) | 2022-03-24 | 2023-09-28 | Pieris Pharmaceuticals Gmbh | Process for purifying fusion proteins |
| IL319272A (en) | 2022-09-21 | 2025-04-01 | Seagen Inc | ROVEL FUSION protein specific for CD137 and CD228 |
| WO2025175123A1 (en) | 2024-02-16 | 2025-08-21 | Seagen Inc. | Methods of treating cancer using fusion proteins specific for cd137 and cd228 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3779221D1 (de) | 1986-08-19 | 1992-06-25 | Genentech Inc | Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und -zytokinen. |
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| NZ285664A (en) | 1994-05-18 | 1998-07-28 | Inhale Therapeutic Syst | Dry powder interferon composition adapted for pulmonary delivery |
| DE4417598A1 (de) | 1994-05-19 | 1995-12-14 | Max Planck Gesellschaft | Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen |
| WO1996023879A1 (en) | 1995-01-30 | 1996-08-08 | Terrapin Technologies, Inc. | Glubodies - multiplicities of proteins capable of binding a variety of small molecules |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| DE19641876B4 (de) | 1996-10-10 | 2011-09-29 | Iba Gmbh | Streptavidinmuteine |
| WO1998016873A1 (en) | 1996-10-14 | 1998-04-23 | Firm Forsat Ltd. | Method for preparing dispersions of chromogenic components |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
| RS50144B (sr) | 1998-06-08 | 2009-03-25 | F. Hoffmann-La Roche Ag., | Primena peg-inf-alfa 2a i ribavirina za proizvodnju leka za lečenje hroničnog hepatitisa c |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| CA2440582A1 (en) | 2001-03-09 | 2002-10-03 | Dyax Corp. | Serum albumin binding moieties |
| WO2003029462A1 (en) * | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| AU2001298053A1 (en) | 2001-09-27 | 2003-04-14 | Pieris Proteolab Ag | Muteins of apolipoprotein D |
| AU2003275958A1 (en) * | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| WO2005019254A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of a bilin-binding protein with affinity for a given target |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| JP2007284351A (ja) | 2004-07-27 | 2007-11-01 | Osaka Bioscience Institute | アミロイド蛋白質の凝集を抑制する物質とその作用 |
| EP2899277A1 (en) | 2004-11-26 | 2015-07-29 | Pieris AG | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| EP1929073A4 (en) | 2005-09-27 | 2010-03-10 | Amunix Inc | PROTEIN MEDICAMENT AND ITS USE |
| SG173332A1 (en) | 2006-08-01 | 2011-08-29 | Pieris Ag | Muteins of tear lipocalin and methods for obtaining the same |
| ES2354653T3 (es) * | 2006-08-01 | 2011-03-16 | Pieris Ag | Muteínas de lipocalina lacrimal y procedimientos para obtener las mismas. |
| EP2235053A1 (en) | 2007-10-19 | 2010-10-06 | Abbott Laboratories | Glycosylated mammalian ngal and use thereof |
| JP5711118B2 (ja) | 2008-06-24 | 2015-04-30 | テクニッシュ ウニヴェルジテート ミュンヘン | 所与の標的に対してアフィニティーを有するｈＮＧＡＬおよび類縁タンパク質のムテイン |
| EP2510357B1 (en) * | 2009-12-07 | 2016-03-30 | Pieris AG | Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target |
| US9051382B2 (en) | 2010-08-16 | 2015-06-09 | Pieris Ag | Human neutrophil gelatinase-associated lipocalin (hNGAL) muteins that bind hepcidin and nucleic acid encoding such |
| CA2817779C (en) | 2010-11-15 | 2019-02-19 | Pieris Ag | Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3) |
| WO2014076321A1 (en) * | 2012-11-19 | 2014-05-22 | Pieris Ag | Novel specific-binding polypeptides and uses thereof |
| CN105246503A (zh) | 2013-03-14 | 2016-01-13 | 第一三共株式会社 | Pcsk9的新颖结合蛋白 |
| WO2015104406A2 (en) * | 2014-01-13 | 2015-07-16 | Pieris Ag | Multi-specific polypeptide useful for localized tumor immunomodulation |
| KR20170105609A (ko) | 2015-01-28 | 2017-09-19 | 피어이스 파마슈티컬즈 게엠베하 | 신생혈관형성에 특이적인 신규한 단백질 |
| EA035824B1 (ru) | 2015-02-18 | 2020-08-17 | Пайерис Фармасьютикалс Гмбх | Новые белки, специфичные к пиовердину и пиохелину |
| EP3292137B1 (en) | 2015-05-04 | 2022-09-07 | Pieris Pharmaceuticals GmbH | Proteins specific for cd137 |
| JP6783797B2 (ja) | 2015-05-04 | 2020-11-11 | ピエリス ファーマシューティカルズ ゲーエムベーハー | 抗がん融合ポリペプチド |
| SMT202300026T1 (it) * | 2015-05-18 | 2023-03-17 | Pieris Pharmaceuticals Gmbh | Polipeptide di fusione anti-cancro |
| CA2982034A1 (en) | 2015-05-18 | 2016-11-24 | Pieris Pharmaceuticals Gmbh | Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3) |
| WO2018087108A1 (en) | 2016-11-09 | 2018-05-17 | Pieris Pharmaceuticals Gmbh | Proteins specific for cd137 |
-
2016
- 2016-05-04 EP EP16721149.9A patent/EP3292137B1/en active Active
- 2016-05-04 US US15/571,611 patent/US11261221B2/en active Active
- 2016-05-04 ES ES16721149T patent/ES2932425T3/es active Active
- 2016-05-04 EP EP22193830.1A patent/EP4177262A1/en active Pending
- 2016-05-04 MX MX2017014082A patent/MX2017014082A/es unknown
- 2016-05-04 WO PCT/EP2016/059959 patent/WO2016177762A1/en not_active Ceased
- 2016-05-04 RU RU2017135599A patent/RU2736312C2/ru active
- 2016-05-04 KR KR1020177034948A patent/KR102734408B1/ko active Active
- 2016-05-04 JP JP2017557299A patent/JP6884708B2/ja active Active
- 2016-05-04 NZ NZ736560A patent/NZ736560A/en unknown
- 2016-05-04 SG SG11201708339QA patent/SG11201708339QA/en unknown
- 2016-05-04 CA CA2980839A patent/CA2980839C/en active Active
- 2016-05-04 CN CN201680025274.3A patent/CN107820500B/zh active Active
- 2016-05-04 DK DK16721149.9T patent/DK3292137T3/da active
- 2016-05-04 CN CN202210118268.XA patent/CN114573680A/zh active Pending
- 2016-05-04 PH PH1/2017/501583A patent/PH12017501583B1/en unknown
- 2016-05-04 AU AU2016258952A patent/AU2016258952C1/en active Active
-
2017
- 2017-09-01 ZA ZA2017/05960A patent/ZA201705960B/en unknown
- 2017-09-14 IL IL254516A patent/IL254516B/en unknown
- 2017-11-02 CL CL2017002767A patent/CL2017002767A1/es unknown
-
2021
- 2021-03-09 JP JP2021036823A patent/JP7149363B2/ja active Active
-
2022
- 2022-01-19 US US17/579,392 patent/US12195503B2/en active Active
- 2022-09-26 JP JP2022152103A patent/JP7477905B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017002767A1 (es) | Nuevas proteínas específicas para cd137. | |
| MX2017009767A (es) | Nuevas proteínas específicas para la angiogénesis. | |
| CL2021000207A1 (es) | Nuevas proteínas de fusión específicas para cd137 y pd-l1 | |
| DOP2017000191A (es) | Nuevas proteínas específicas para pioverdina y pioquelina | |
| BR112017018368A2 (pt) | composições contendo rna para o tratamento de doenças tumorais | |
| MX2018000447A (es) | Novedosas proteinas especificas para lag-3. | |
| CO2018012374A2 (es) | Moléculas de anticuerpo para el tratamiento del cáncer | |
| MX390894B (es) | Polipéptido de fusión anti-cáncer. | |
| MX2018001567A (es) | Novedosos polipeptidos de fusion especificos para lag-3 y pd-1. | |
| ECSP15025845A (es) | Anticuerpos anti-ceacam5 y usos de éstos | |
| MX2017014083A (es) | Polipeptido de fusion anti-cancer. | |
| EA201891186A1 (ru) | Антитела, нейтрализующие вирус иммунодефицита человека | |
| GT201800102A (es) | Polipéptidos que inhiben cd4ol | |
| MX2014010755A (es) | Moleculas de union humanas que pueden unirse a los virus de la influenza b y neutralizarlos, y sus usos. | |
| AR112069A1 (es) | Inmunoglobulinas que fijan aggrecan | |
| EA201591925A1 (ru) | Терапевтические композиции и их применение | |
| BR112017009552A8 (pt) | Métodos para alvejar o controle transcricional em regiões de super-realçador | |
| MX2019008434A (es) | Muteínas de lipocalina con afinidad de unión por lag-3. | |
| BR112018002530A2 (pt) | combinações e usos e tratamentos destas | |
| BR112014024033A8 (pt) | Formulação vesicular, método para o tratamento da rosácea e uso de um ou mais fosfo, sulfolipídios e surfactantes | |
| AR115878A1 (es) | Proteínas de fusión específicas para cd137 y pd-l1 | |
| CO2025003550A2 (es) | Anticuerpos que unen cd228 | |
| BR112016022318A2 (pt) | método, composição farmacêutica para uso no tratamento de doenças de retina e uso de um anticorpo |